Literature DB >> 11864326

Resistance to amikacin and gentamicin among Gram-negative bloodstream isolates in a university hospital between 1989 and 1994.

Stephan Harbarth1, Peter Rohner, Edith Safran, Jorge Garbino, Raymond Auckenthaler, Didier Pittet.   

Abstract

OBJECTIVE: To characterize antimicrobial resistance patterns to amikacin (AN) and gentamicin (GM) among Gram-negative bloodstream isolates and to determine the possible relationship between use of AN and GM and the occurrence of antibiotic resistance during a 6-year period.
METHODS: Standard media and techniques of isolation and identification were used. Antimicrobial susceptibility testing was performed with the disk diffusion method and API rapid ATB E strips. Data on consumption of aminoglycosides were collected by the central hospital pharmacy and were expressed as daily defined doses.
RESULTS: One thousand nine hundred and four bloodstream isolates were tested for AN and GM susceptibility between 1989 and 1994. Activities of AN and GM remained high during the study period against most isolates of Gram-negative bacteria. No relationship could be observed between the use of AN/GM and the rate of AN/GM resistance. Nosocomial Gram-negative bloodstream isolates showed a higher degree of resistance towards both AN (3.9% of all nosocomial isolates) and GM (7.9%) than community-acquired isolates (1.8% toward AN and 3.1% towards GM, respectively). There was a significant increase (P=0.004) in the risk of GM resistance in patients with nosocomial Gram-negative bacteremia detected more than 14 days after admission. The proportion of GM-susceptible Pseudomonas aeruginosa isolates decreased linearly from 97% for infections acquired between day 3 and day 10 following admission to 80% for bacteremia developing 30 days or more after admission (P=0.008).
CONCLUSIONS: AN and GM remain highly active antimicrobial drugs for treatment of GNB in times of growing resistance to cephalosporins and fluoroquinolones.

Entities:  

Year:  1998        PMID: 11864326     DOI: 10.1111/j.1469-0691.1998.tb00669.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  7 in total

1.  Comparison of hospital-wide and unit-specific cumulative antibiograms in hospital- and community-acquired infection.

Authors:  F Lamoth; A Wenger; G Prod'hom; Y Vallet; C Plüss-Suard; J Bille; G Zanetti
Journal:  Infection       Date:  2010-06-16       Impact factor: 3.553

2.  Multicentre study of antimicrobial resistance and antibiotic consumption among 6,780 patients with bloodstream infections.

Authors:  U Frank; E M Kleissle; F D Daschner; L Leibovici; M Paul; S Andreassen; H C Schonheyder; R Cauda; E Tacconelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-12       Impact factor: 3.267

3.  Prophylactic Antibiofilm Activity of Antibiotic-Loaded Bone Cements against Gram-Negative Bacteria.

Authors:  Andréa Cara; Tristan Ferry; Frédéric Laurent; Jérôme Josse
Journal:  Antibiotics (Basel)       Date:  2022-01-21

4.  Childhood septicemia in Nepal: documenting the bacterial etiology and its susceptibility to antibiotics.

Authors:  Shamshul Ansari; Hari Prasad Nepal; Rajendra Gautam; Sony Shrestha; Puja Neopane; Brihaspati Rimal; Fuleshwar Mandal; Safiur Rahman Ansari; Moti Lal Chapagain
Journal:  Int J Microbiol       Date:  2014-12-25

5.  Colistin Resistance among Enterobacteriaceae Isolated from Clinical Samples in Gaza Strip.

Authors:  Mohammad Qadi; Safaa Alhato; Rasha Khayyat; Abdelraouf A Elmanama
Journal:  Can J Infect Dis Med Microbiol       Date:  2021-04-20       Impact factor: 2.471

6.  Antibiotic consumption and healthcare-associated infections caused by multidrug-resistant gram-negative bacilli at a large medical center in Taiwan from 2002 to 2009: implicating the importance of antibiotic stewardship.

Authors:  I-Ling Chen; Chen-Hsiang Lee; Li-Hsiang Su; Ya-Feng Tang; Shun-Jen Chang; Jien-Wei Liu
Journal:  PLoS One       Date:  2013-05-30       Impact factor: 3.240

7.  Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children.

Authors:  Meltem Polat; Soner Sertan Kara
Journal:  Infect Drug Resist       Date:  2017-11-01       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.